Dustri Online Services

Books: 0	Journals: 2	Articles: 3

Abstract

Clinical Nephrology, Vol. 81 – No. 3/2014 (216-223)

Goodpasture’s syndrome with concomitant immune complex mixed membranous and proliferative glomerulonephritis

Vesna Jurčić¹, Alenka Vizjak¹, Andreja Aleš Rigler², Jera Jeruc¹, Jörgen Wieslander³, and Dušan Ferluga¹

¹Institute of Pathology, Faculty of Medicine, University of Ljubljana, ²Clinical Department of Nephrology, University Clinical Center, Ljubljana, Slovenia, and ³Department of Nephrology, Lund University Hospital, Lund, Sweden
Classical Goodpasture’s (GP) syndrome is a monophasic illness characterized by pulmonary hemorrhage and rapidly progressive glomerulonephritis with linear IgG deposition along the glomerular and distal tubular basement membrane and estructive necrotizing diffuse extracapillary crescentic glomerulonephritis. The majority of patients have circulating anti-glomerular basement membrane (GBM) antibodies, detectable with standard anti-GBM ELISA. Concurrence of GP syndrome with proliferative glomerulonephritis has only rarely been described. In this report, for the first time we describe in a 21-year-old woman GP syndrome with 50% crescentic sclerosing glomerulonephritis with linear immunofluorescence characteristic of anti-GBM pathogenesis, combined with mixed membranous and membranoproliferative glomerulonephritis with granular immunofluorescence and subepithelial, mesangial and subendothelial deposits characterizing immune complex pathogenesis. The clinical picture was also unusual for GP syndrome, manifesting a recurrent but non-progressive course, nephrotic syndrome, normal renal function and low values of anti-GBM antibodies, identified only by novel more sensitive techniques.Correspondence to:
Dr. Vesna Jurčić, MD, PhD
Institute of Pathology, Faculty of Medicine
University of Ljubljana
Korytkova 2, 1105 Ljubljana, Slovenia
Email: [email protected]

Abstract

Clinical Neuropathology, Vol. 35 – No. 2/2016 (72-77)

Fatal recurrent dermatoneuro syndrome associated with systemic AL amyloidosis

Lea Leonardis¹, Dominika Novak Pihler², Matija Zupan³, Alenka Vizjak⁴, Neža Lebič Belcijan⁴, Vesna Jurčić⁴, and Mara Popović⁴

¹Institute of Clinical Neurophysiology, University Medical Center Ljubljana, Ljubljana, ²Murska Sobota General Hospital, Rakican, Murska Sobota, ³Neurology Department, University Medical Center Ljubljana, and ⁴Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
A male patient is presented with long-lasting paraproteinemia of monoclonal IgG λ, who suffered from recurrent, and until the last one, mostly reversible episodes of dermatoneuro syndrome, described exclusively in scleromyxedema. The skin biopsy revealed λ-light chain amyloid deposition instead of changes typical for scleromyxedema. Systemic AL amyloidosis was diagnosed post mortem since the patient had no clinical signs of any other organ impairment except skin and brain. Neuropathology is described and possible etiopathogenesis of brain involvement is considered.Correspondence to:
Mara Popović, MD, PhD
Institute of Pathology, Faculty of Medicine
University of Ljubljana
Korytkova 2, 1000 Ljubljana, Slovenia
Email: [email protected]

Abstract

Clinical Nephrology, Vol. 88 – Suppl. 1/2017 (S27-S31)

Rituximab for the treatment of membranous nephropathy: a single-center experience

Andreja Aleš Rigler¹, Alexander Jerman¹, Aleša Orsag¹, Nika Kojc², Damjan Kovač¹, Andrej Škoberne¹, Špela Borštnar¹, Željka Večerić Haler¹, Nuša Avguštin¹, Radoslav Kveder¹, Dušan Ferluga², Alenka Vizjak², and Jelka Lindič¹

¹Department of Nephrology, University Medical Center Ljubljana, and  ²Institute of Pathology, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Background: Treatment of idiopathic membranous nephropathy with rituximab was introduced more than a decade ago following experimental data that suggested involvement of B-cell-mediated reactions in its pathogenesis. It was a logical step towards a more selective therapy with less severe side effects as compared to the recommended first-line immunosuppressive therapy with corticosteroids and different immunosuppressant drugs. Methods: We retrospectively analyzed the anonymous data of patients who were treated with rituximab for idiopathic membranous nephropathy at our institution from January 2006 to July 2016. Daily proteinuria and serum creatinine were analyzed 3, 6, 9, and 12 months after rituximab application. The patients were divided into 4 groups according to proteinuria. We separately analyzed remission rates in the whole group and in groups with different quantity of daily proteinuria. Other history data and laboratory parameters were also compared within different groups of patients. Results: The study involved 29 rituximab treatments in 26 patients: 7 (26.9%) female and 19 (73.1%) male patients. In 16 out of 29 treatment cases (55.1%), patients had been previously treated with cyclophosphamide and steroids, or cyclosporine with low dose of steroids, or both. In 72.4% of patients, antiphospholipase A₂ receptor antibodies were present. In 2 cases of treatment (6.9%), patients received rituximab 375 mg/m² of body surface area in 3 and 4 weekly doses, respectively. In all other cases, repeated rituximab applications were given as needed according to the levels of circulating CD-20 B-cells. The total remission rate in our cohort of patients was 37.9% (11 out of 29 cases). The average serum creatinine in the group of patients who achieved remission was significantly lower than in the group without remission (86.5 vs. 155.5 µmol/L, p = 0.003). There was no difference in the duration of the disease prior to treatment with rituximab between the groups (53.6 and 56.4 months, respectively). The remission rate was highest in the group with daily proteinuria less than 4 g per day (83.3%). There were no remissions in the group of patients with daily proteinuria more than 12 g per day. Conclusion: The remission rate after rituximab treatment in our cohort of patients with idiopathic membranous nephropathy was lower than in other studies. The reason for this is possibly the application of a single dose of rituximab in the majority of patients, which might have been insufficient in patients with higher proteinuria. Correspondence to:
Andreja Aleš Rigler, MD, PhD
Department of Nephrology
University Medical Center Ljubljana
Zaloška 7, 1000 Ljubljana, Slovenia
Email: [email protected]

Shopping Overview
Type	Qtty	Discount	VAT	Price
Your basket is empty

View Cart

Search Results

Shopping Overview

Send us an E-Mail